MarketWatch

Emory University and Micron Biomedical Launch First-in-Human Clinical Trial of Next-Generation Rotavirus Vaccine Delivered via Dissolvable Microarray Technology

The MarketWatch News Department was not involved in the creation of this content. -- Trial represents first-ever CDC-sponsored clinical trial of vaccine delivered via "patch" technology and utilizes ...
technologynetworks

The Staying Power of Chromosomal Microarray Analysis: Innovations on the Horizon Will Future Proof Tried and True Technology

Genetic research labs are under constant pressure to increase their throughput while bringing down costs. Even though emerging new technologies can help labs expand their analysis capabilities, it’s ...
Business Wire

Newly Published Data Supports Effective Delivery of DNA-Based Vaccines Using Vaxxas’ High-Density Microarray Patch (HD-MAP) Delivery Technology

Reported Data Supports the Potential Extension of HD-MAP Vaccine Delivery to Oncology Indications Recently published data generated by researchers at The University of Queensland and Vaxxas shows ...
Benzinga.com

Needle-Free Vaccine Technology For Measles-Rubella: Bill & Melinda Gates Foundation Fund Mass Production

The Gates foundation funds a US-based life science company for needle-free vaccine technology. The method utilizes dissolvable microneedles on a patch-like device Get the Strategy to Trade Pre-Fed ...
NBC4 Columbus

Emory University and Micron Biomedical Launch First-in-Human Clinical Trial of Next-Generation Rotavirus Vaccine Delivered via Dissolvable Microarray Technology

Trial represents first-ever CDC-sponsored clinical trial of vaccine delivered via “patch” technology and utilizes Micron’s first-in-class dissolvable microarray technology Research builds on Emory’s ...